sorafenib has been researched along with Disease Exacerbation in 341 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 33 (9.68) | 29.6817 |
| 2010's | 268 (78.59) | 24.3611 |
| 2020's | 40 (11.73) | 2.80 |
| Authors | Studies |
|---|---|
| Adnane, L; Auclair, D; Bollag, G; Cao, Y; Carter, C; Chen, C; Eveleigh, D; Gawlak, S; Gedrich, R; Liu, L; Lynch, M; McHugh, M; McNabola, A; Post, LE; Riedl, B; Rong, H; Rowley, B; Shujath, J; Tang, L; Taylor, I; Trail, PA; Vincent, P; Voznesensky, A; Wilhelm, SM; Wilkie, D; Zhang, X | 1 |
| Iwamoto, H; Kajiwara, A; Kamachi, N; Kawaguchi, T; Koga, H; Kuromatsu, R; Nakano, M; Niizeki, T; Noda, Y; Okamura, S; Shimose, S; Shirono, T; Tanaka, M; Torimura, T | 1 |
| Chang, WT; Chen, KY; Chen, SC; Cheng, TS; Chuang, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Hsu, CT; Hsu, PY; Huang, CF; Huang, CI; Huang, JF; Jang, TY; Ko, YM; Liang, PC; Lin, CC; Lin, YH; Lin, ZY; Tsai, YS; Wang, CW; Wei, YJ; Yeh, ML; Yu, ML | 1 |
| Cai, J; Ding, J; Jin, Y; Xu, Q; Yang, R; Zhu, C; Zhu, F | 1 |
| Antonuzzo, L; Basso, U; Bersanelli, M; Bimbatti, D; Buti, S; Carella, C; Conca, R; De Giorgi, U; Doni, L; Fornarini, G; Galli, L; Gambale, E; Giorgione, R; Naglieri, E; Nesi, G; Pignata, S; Procopio, G; Rebuzzi, SE; Roviello, G; Santini, D; Sbrana, A; Stellato, M | 1 |
| Eguchi, H; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Nagano, H; Ogawa, K; Seo, S; Takada, Y | 1 |
| Chung, IJ; Hong, YS; Kang, WK; Kang, YK; Kim, YH; Lee, KH; Nam, BH; Park, YI; Park, YS; Ryoo, BY; Ryu, MH; Shen, L; Shin, DB; Yang, SH; Yeh, KH; Yoo, C; Zang, DY | 1 |
| Chen, Y; Chen, Z; Chi, X; Hong, H; Lv, L; Yu, J | 1 |
| Chen, Y; Chi, P; Deng, L; Fan, Z; Huang, F; Huang, X; Jiang, L; Li, X; Liang, X; Lin, R; Liu, H; Liu, Q; Luo, X; Shao, R; Shi, P; Sun, J; Tu, S; Wang, Y; Wang, Z; Xu, N; Xu, Y; Xuan, L; Yang, K; Zhang, Y | 1 |
| Chen, M; Cheng, CL; Chin, DW; Law, CT; Lee, D; Lee, JM; Ng, IO; Shen, J; Tsang, FH; Wei, L; Wong, CC; Wong, CM | 1 |
| Airoldi, A; Antonelli, B; Cesarini, L; Donato, MF; Iavarone, M; Invernizzi, F; Lampertico, P; Maggi, U; Manini, MA; Mazza, S; Rossi, G; Sangiovanni, A; Saverio Belli, L; Zavaglia, C | 1 |
| Belt, P; Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Kline, Z; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N | 1 |
| Au, CH; Chan, TL; Ip, HW; Kwong, YL; Lam, SSY; Lau, JSM; Lee, HKK; Leung, AYH; Leung, GMK; Li, W; Luk, TH; Ma, ESK; Ng, NKL; Tsui, SP; Yang, N; Yip, SF; Zhang, C | 1 |
| Chang, CS; Lee, SW; Lee, TY; Peng, YC; Yang, SS; Yeh, HZ | 1 |
| Liu, J; Qiu, WC; Shen, XY; Sun, GC | 1 |
| Bangaru, S; Marrero, JA; Singal, AG | 1 |
| Aikata, H; Aino, H; Arai, Y; Furuse, J; Hino, K; Ido, A; Ikeda, M; Isoda, N; Izumi, N; Johnson, PJ; Kawabe, N; Kokudo, N; Kudo, M; Kuzuya, T; Nakao, K; Nojiri, S; Okita, K; Okusaka, T; Tanabe, N; Torimura, T; Tsumura, H; Ueshima, K; Wada, Y; Yamasaki, T; Yasui, K; Yokosuka, O; Yoshimura, K | 1 |
| Abo Elseud, Y; Albarrak, J; Mohanty, A; Salamah, R; Shaaban, A | 1 |
| Beale, S; Boland, A; Chaplin, M; Duarte, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Houten, R; Shenoy, A | 1 |
| Gao, Y; Jiang, JD; Li, K; Li, ZR; Xue, ST; Yi, H; Zhao, LY | 1 |
| abuTaleb, F; Ebian, H; El Shorbagy, S; Elbana, KA; Haggag, R; Harb, OA; Labib, HA; Mohammed, MS; Rashied, HA | 1 |
| Hua, S; Li, W; Li, Y; Lu, L; Ma, F; Wang, H; Xu, H; Yang, X; Zhan, M | 1 |
| Abou-Alfa, GK; Blanc, JF; Cheng, AL; Daniele, B; Guerra, I; Kelley, RK; Marteau, F; Mollon, P; Valcheva, V; Yau, T | 1 |
| Manoharan, R; Natarajan, SR; Ponnusamy, L; Thangaraj, K | 1 |
| Chang, CS; Lee, SW; Lien, HC; Peng, YC; Tung, CF | 1 |
| Cheng, Z; Jin, D; Wei-Qi, J | 1 |
| Gong, FL; Guo, XL; Li, YS; Wang, L; Yang, XX; Yu, LG; Zhang, XK; Zhao, L | 1 |
| Abou-Alfa, GK; Capanu, M; Chou, JF; Do, RKG; El Dika, I; Harding, JJ; Hrabovsky, AD; Ly, M; Ma, J; Millang, B; O'Reilly, EM; Shia, J | 1 |
| Aikata, H; Aisaka, Y; Ando, Y; Azakami, T; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawaoka, T; Kodama, K; Kosaka, Y; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Naeshiro, N; Nakahara, T; Nonaka, M; Suehiro, Y; Takahashi, S; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S; Yamaoka, K; Yamauchi, M | 1 |
| Bahra, M; Bechstein, W; Bischoff, S; Bitzer, M; Denzlinger, C; Gellert, K; Ghadimi, M; Hinke, A; Hofheinz, R; Lammert, F; Liersch, T; Lindig, U; Maschmeyer, G; Oettle, H; Pelzer, U; Riess, H; Sinn, M; Striefler, JK; Stübs, P; Waldschmidt, D | 1 |
| Li, D; Li, W; Liu, M; Yang, D; Zhang, Y; Zhao, S | 1 |
| Chao, Y; Chen, YT; Cheng, TY; Hou, MC; Huang, YH; Lee, PC | 1 |
| Ahn, SH; Kim, BK; Kim, DY; Kim, KH; Kim, S; Kim, SU; Park, JY | 1 |
| Bi, L; Chen, F; Chen, W; Du, L; Feng, M; Jiang, Y; Jiao, Q; Meng, P; Ren, Y; Tang, B; Wang, C; Wang, Q; Wang, Y; Zhou, F | 1 |
| Shi, L; Su, D; Wu, B | 1 |
| Hagiwara, H; Hikita, H; Inada, M; Kodama, T; Maesaka, K; Mita, E; Ohkawa, K; Oshita, M; Sakamori, R; Tahata, Y; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, R | 1 |
| Basu, B; Ben Khaled, N; Benckert, J; Berg, T; de Toni, EN; Gasbarrini, A; Jurkeviciute, G; Klümpen, HJ; Kupčinskas, J; Malfertheiner, P; Morkunas, E; Öcal, O; Palmer, D; Pech, M; Ricke, J; Sangro, B; Schütte, K; Seidensticker, M; Seidensticker, R; Sengel, C; Valle, JW; Wildgruber, M | 1 |
| Chen, L; Chen, S; Du, Y; Jiang, Z; Li, Q; Xu, B; Yang, L; Zeng, Z | 1 |
| Brezinová, B; Chovanec, M; Dubovan, P; Gomolčáková, J; Jurišová, S; Mardiak, J; Mego, M; Rejlekova, K | 1 |
| Cai, JB; Dong, ZR; Fan, J; Ke, AW; Li, T; Shi, GM; Yang, YF; Zhou, W | 1 |
| Cho, M; Hong, YM; Yoon, KT | 1 |
| Bai, Y; Cang, S; Chen, M; Chen, Y; Chen, Z; Cui, J; Du, C; Fan, J; Gao, Z; Gu, S; Guo, Y; Huang, M; Jia, W; Li, Q; Liu, B; Liu, C; Lu, Y; Mao, Y; Meng, Z; Qin, Y; Ren, Z; Shan, Y; Shao, G; Shi, X; Teng, G; Wang, J; Wang, Y; Wu, J; Xia, F; Xing, B; Xu, A; Xu, J; Yang, W; Yang, Y; Yin, G; Yin, T; Zhang, B; Zhou, H | 1 |
| Ambrosi, A; Bargellini, I; Chandan, S; Cotsoglou, C; Facciorusso, A; Mohan, BP; Paolillo, R; Ramai, D; Renzulli, M; Sacco, R; Tartaglia, N | 1 |
| Chen, YT; Chu, XY; Xiang, D; Zhao, XY | 1 |
| Ahn, SH; Han, KH; Kang, JH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY | 1 |
| Chang, HH; Chen, JS; Chia-Hsun Hsieh, J; Chou, WC; Hou, MM; Huang, CY; Lee, CL; Lin, YC; Teng, W; Tseng, YT; Yang, TS | 1 |
| Chen, T; Cui, M; Cui, Y; Ge, C; Huo, Q; Li, H; Li, J; Sun, J; Tian, H; Xie, H; Yao, M; Zhao, F | 1 |
| Abe-Chayama, H; Aikata, H; Chayama, K; Daijo, K; Fujino, H; Hiramatsu, A; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Makokha, GN; Masaki, K; Masuda, K; Miki, D; Morio, K; Nagaoki, Y; Nakahara, T; Nakamura-Inagaki, Y; Nelson Hayes, C; Ochi, H; Ono, A; Teraoka, Y; Tsuge, M; Uchida, T; Zhang, Y | 1 |
| Cho, EJ; Cho, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, KW; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ | 1 |
| Bruix, J; Cleton, A; Drenth, HJ; Fiala-Buskies, S; Keunecke, A; Meinhardt, G; Ploeger, B; Reinecke, I; Solms, A | 1 |
| Buder, R; Galle, PR; Ganten, TM; Gerken, G; Göhler, T; Koschny, R; Malfertheiner, P; Schott, E; Stauber, RE; Walther, M | 1 |
| Chen, RX; Cui, JF; Dong, G; Dong, YY; Gao, DM; Li, JH; Ma, H; Ma, M; Ren, ZG; Yao, RR; Zhang, R; Zheng, QD | 1 |
| Chao, Y; Chen, YT; Hou, MC; Huang, YH; Huo, TI; Lee, FY; Lee, MH; Lee, PC; Li, CP; Lin, HC; Su, CW | 1 |
| Bao, B; Delaney, J; Groves, K; Ho, G; Kossodo, S; Morin, J; Narayanan, N; Peterson, JD; Rajopadhye, M; Tseng, JC; Zhang, J | 1 |
| Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ | 1 |
| Li, W; Sun, X; Tan, G; Wang, P; Zhai, B; Zhu, M | 1 |
| Arvat, E; Berardelli, R; Felicetti, F; Gallo, M; Marchisio, F; Nervo, A; Piovesan, A | 1 |
| Basara, N; Burchert, A; Ditschkowski, M; Dreger, P; Fey, MF; Finck, A; Finke, J; Giagounidis, A; Götze, K; Kobbe, G; Lübbert, M; Metzelder, SK; Meyer, RG; Neubauer, A; Pabst, T; Salih, HR; Scholl, S; Schroeder, T; Wollmer, E | 1 |
| Cen, J; He, Q; Hu, C; Hu, J; Hui, L; Ji, Y; Jiang, K; Kienast, Y; Li, W; Liu, X; Qiu, Z; Tian, F; Wang, Z; Zhang, H | 1 |
| Abdel-Rahman, O; Eissa, M; El Gewaity, M; Farag, K; Ghonaim, A; Nada, Y; Rashad, N; Saadawi, I; Sheha, A | 1 |
| Bi, Y; Casak, S; Goldberg, KB; Jiang, X; Keegan, P; Lemery, S; Liu, J; McKee, AE; Patel, A; Pazdur, R; Pelosof, L; Pierre, V; Rodriguez, L; Zirkelbach, JF | 1 |
| Chen, M; Chen, S; Jiang, C; Kuang, M; Li, B; Li, J; Lin, M; Mei, J; Peng, Z; Qian, G; Wang, Y; Wei, M; Xie, X | 1 |
| Aramaki, T; Asagi, A; Furuse, J; Hosokawa, A; Ikeda, M; Ishii, H; Kaneko, S; Kato, N; Okusaka, T; Sano, K; Sato, T; Sugimoto, R; Suzuki, E; Yamaguchi, K; Yasui, K | 1 |
| Meyer, T | 1 |
| Cho, EJ; Cho, YY; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Yoon, JH; Yu, SJ | 1 |
| Deptala, A; Fartoux, L; Graham, J; Hocke, J; Loembé, AB; Ma, YT; Meyer, T; Palmer, DH; Peck-Radosavljevic, M; Ross, P; Schnell, D; Studeny, M | 1 |
| Baumhauer, A; Bodoky, G; Bruix, J; Cabrera, R; Caparello, C; Chang, C; Finn, RS; Gerolami, R; Granito, A; Huang, YH; LeBerre, MA; Meinhardt, G; Merle, P; Pracht, M; Rosmorduc, O; Sun, W; Yokosuka, O | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I | 1 |
| Cai, W; Chen, YH; Dong, BJ; Huang, JW; Huang, YR; Kong, W; Li, MY; Xue, W; Yuan, YC; Zhang, J; Zhou, LX | 1 |
| Heo, YA; Syed, YY | 1 |
| Duo, J; Ma, X; Zhao, Y; Zhu, H | 1 |
| Abo, D; Inaba, Y; Kodama, Y; Matsuo, K; Nakatsuka, A; Nishiofuku, H; Okubo, H; Sato, Y; Takaki, H; Yamakado, K; Yasumoto, T | 1 |
| Abraham, IE; Dudek, AZ; Liu, LI; Schmidt, TM; Uy, AB | 1 |
| Aliberti, C; Benvegnù, L; Bernardi, M; Bortolini, E; Borzio, F; Borzio, M; Bucci, L; Burra, P; Cabibbo, G; Caturelli, E; Ciccarese, F; Cillo, U; Colecchia, A; Cozzolongo, R; Di Marco, M; Faggiano, C; Farinati, F; Felder, M; Fornari, F; Foschi, FG; Frigo, AC; Gasbarrini, A; Giannini, EG; Grasso, A; Marignani, M; Marra, F; Masotto, A; Morisco, F; Nardone, G; Noaro, G; Olivani, A; Pawlik, TM; Rapaccini, GL; Sacco, R; Svegliati-Baroni, G; Trevisani, F; Vicari, S; Virdone, R; Vitale, A; Zoli, M | 1 |
| Braicu, EI; Chekerov, R; De Gregorio, N; du Bois, A; El-Balat, A; Fridrich, C; Harter, P; Hilpert, F; Krabisch, P; Lorenz, R; Lueck, HJ; Mahner, S; Markmann, S; Oskay-Oezcelik, G; Potenberg, J; Richter, R; Schmidt, M; Sehouli, J | 1 |
| Bilska, K; Raciborska, A | 1 |
| Deshpande, H; Donadio, A; Hurwitz, ME; Kelly, WK; Markowski, P; Mehnert, JM; Mortazavi, A; Patel, J; Petrylak, DP; Stein, MN; Yao, X | 1 |
| Hu, J; Li, L; Liu, L; Wang, E; Wang, M; Zhao, W; Zhao, Y | 1 |
| Chen, J; Chen, RX; Cui, JF; Gao, DM; Lin, XH; Liu, HH; Ma, M; Ren, ZG; Zhang, R | 1 |
| Fu, QH; Hu, QD; Huang, BF; Jin, PP; Que, RS; Shao, SY; Wu, WT; Zhao, XY | 1 |
| Ma, CG; Shi, GH; Wang, HK; Xu, WH; Ye, DW; Zhang, HL; Zhou, LP | 1 |
| Amir, E; Frizziero, M; Hubner, RA; Knox, JJ; Lamarca, A; McNamara, MG; Nuttall, C; Pihlak, R; Slagter, AE; Tariq, N; Valle, JW | 1 |
| Goldstein, DA; Leshno, M; Shlomai, A | 1 |
| Carapinha, J; Hamdy Elsisi, G; Nada, Y; Rashad, N | 1 |
| Han, Z; He, Z; Wang, C; Wang, Q | 1 |
| Ito, T; Matsushita, Y; Miyake, H; Motoyama, D; Otsuka, A; Sugiyama, T; Tamura, K; Watanabe, H | 1 |
| Fang, Q; Lu, J; Lu, Y; Wu, H; Xie, C; Xiong, Y; Yin, Z | 1 |
| Austin, R; Brose, MS; Grevel, J; Huang, F; Jentsch, G; Lettieri, J; Meinhardt, G; Mitchell, D; Peña, CEA; Ploeger, BA; Prins, NH; Schlumberger, M | 1 |
| Cheng, X; Huang, Y; Li, T; Song, Z; Sun, P; Zheng, Q | 1 |
| Chen, L; Chen, LJ; Chen, Y; Guo, J; Meng, S; Tan, ZR; Tang, J; Xiao, J; Xu, Y; Zhang, W; Zhao, Q; Zheng, B | 1 |
| Bai, W; Cai, H; Fan, D; Han, G; Li, X; Liu, L; Niu, J; Wang, E; Xia, D; Xia, J; Yin, Z; Yuan, J | 1 |
| Bouattour, M; Hulin, A; Stocco, J | 1 |
| Cheng, Z; Cui, X; Ding, J; Fu, G; Hou, C; Hou, G; Jiang, W; Jin, GZ; Li, H; Li, SC; Liu, H; Sun, W; Wang, H; Wang, R; Xiang, DM; Zhang, C; Zhou, T | 1 |
| Anderson, J; Chao, Y; Choo, SP; Chopra, A; Cruz, CD; Hou, MM; Hsu, C; Ikeda, M; Kang, YK; Kim, TY; Kudo, M; Kuromatsu, R; Moriguchi, M; Numata, K; Yau, T; Yeo, W; Zhao, H | 1 |
| Ankoma-Sey, V; Balogh, J; Boktour, M; Divatia, MK; Duchini, A; Egwim, C; Gaber, AO; Galati, J; Ghobrial, RM; Graviss, EA; Heyne, K; Lunsford, K; McFadden, R; Mobley, C; Monsour, HP; Nguyen, DT; Saharia, A; Victor, DW | 1 |
| Aspord, C; Decaens, T; Granon, A; Kurma, K; Macek Jilkova, Z; Marche, PN; Sengel, C; Sturm, N | 1 |
| Assenat, E; Benhadji, KA; Cleverly, A; Faivre, S; Galle, PR; Gane, E; Giannelli, G; Gueorguieva, I; Hourmand, IO; Kelley, RK; Lahn, M; Merle, P; Siebler, J; Zhao, Y | 1 |
| Ameigeiras, B; Anders, M; Bermúdez, C; Colombato, L; D'Amico, C; Fernández, N; Gadano, A; Gaite, L; Marciano, S; Piñero, F; Reggiardo, V; Ridruejo, E; Romero, G; Silva, J; Silva, M; Zerega, A | 1 |
| Addeo, R; Cennamo, G; Del Prete, S; Iodice, P; Montella, L; Palmieri, R; Russo, P; Sperlongano, P; Sperlongano, R; Vincenzi, B | 1 |
| Bies, RR; Jin, Y; Kang, SP; Karrison, TG; Maitland, ML; Ratain, MJ; Sharma, MR; Stadler, WM; Wu, K | 1 |
| Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W | 1 |
| Annunziata, CM; Azad, N; Calvo, K; Chen, CC; Choyke, P; Davidson, B; Edelman, DC; Henning, R; Kohn, EC; Meltzer, P; Minasian, L; Steinberg, SM; Venkatesan, A; Wood, BJ; Yu, M | 1 |
| Fetterly, GJ; Hylander, BH; Jusko, WJ; Ma, WW; Pawaskar, DK; Repasky, EA; Straubinger, RM | 1 |
| Chan, JA; Jackson, N; Kulke, MH; Malinowski, P; Mayer, RJ; Regan, E | 1 |
| Albiges, L; Di Palma, M; Escudier, B; Fizazi, K; Levy, A; Loriot, Y; Menard, J | 1 |
| Bhoori, S; Bongini, M; Flores Reyes, M; Germini, A; Grossi, G; Mariani, L; Mazzaferro, V; Sposito, C | 1 |
| Bruno, R; Claret, L; Mercier, F | 1 |
| Bay, JO; Blay, JY; Bompas, E; Chaigneau, L; Chevreau, C; Cioffi, A; Clisant, S; Fournier, C; Gauthier, E; Isambert, N; Italiano, A; Le Cesne, A; Penel, N; Ray-Coquard, I; Robin, YM | 1 |
| Cho, JY; Choi, MS; Gwak, GY; Kim, YG; Koh, KC; Lee, JH; Lim, HK; Lim, HY; Min, YW; Paik, SW; Paik, YH; Yoo, BC | 1 |
| Hou, JN; Jiang, MD; Wang, Z; Weng, M; Wu, XL; Xu, GS; Xu, H; Zeng, WZ | 1 |
| Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J | 1 |
| Gong, R; Liu, LR; Nie, LH; Song, TR; Wang, JZ; Wazir, R; Wei, Q; Zhao, RN | 1 |
| Ayuso, C; Bruix, J; Darnell, A; Forner, A; Llarch, N; Reig, M; Rimola, J; Ríos, J; Rodriguez-Lope, C; Torres, F | 1 |
| Arai, Y; Ikeda, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Satake, M; Shimizu, S; Takahashi, H; Ueno, H | 1 |
| Ainora, ME; Annicchiarico, BE; Caracciolo, G; Di Stasio, E; Garcovich, M; Gasbarrini, A; Landolfi, R; Lupascu, A; Pompili, M; Ponziani, F; Rapaccini, GL; Riccardi, L; Roccarina, D; Siciliano, M; Zocco, MA | 1 |
| Donnellan, F; Gill, S; Haque, M; Hashim, AM; Shingina, A; Suen, M; Weiss, AA; Yoshida, EM | 1 |
| Choi, GH; Kang, YK; Kim, KM; Kim, MJ; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Shin, YM | 1 |
| Amoroso, D; Andreuccetti, M; Falcone, A; Fontana, A; Galli, C; Galli, L; Landi, L; Lombardi, G; Porta, C; Zagonel, V; Zustovich, F | 1 |
| Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL | 1 |
| He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB | 1 |
| Dermeche, S; Gravis, G; Guerin, M; Salem, N; Walz, J | 1 |
| Bjarnason, GA; Escudier, B; Esteban, E; Hariharan, S; Hutson, TE; Lim, HY; Lu, DR; Motzer, RJ; Niethammer, A; Pittman, KB; Senico, P | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Svoboda, M; Vyzula, R | 1 |
| Bonington, S; Denton, K; Homer, J; Lee, LW; Mak, SK; Silva, P; Slevin, NJ; Swindell, R; Sykes, AJ; Thomson, DJ; Yap, BK | 1 |
| Adenis, A; Assenat, E; Bennouna, J; Bibeau, F; Boissière, F; Bouché, O; Conroy, T; Crapez, E; Desseigne, F; Francois, E; Galais, MP; Laurent-Puig, P; Mazard, T; Poujol, S; Samalin, E; Seitz, JF; Taieb, J; Thézenas, S; Ychou, M | 1 |
| Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK | 1 |
| Arizumi, T; Hagiwara, S; Inoue, T; Kitai, S; Kudo, M; Minami, Y; Nishida, N; Osaki, Y; Sakurai, T; Takeda, H; Takita, M; Ueshima, K; Yada, N | 1 |
| Cabanillas, ME; Dadu, R; Dong, W; Feng, L; Lai, SY; Regone, RM; Thomas, L | 1 |
| Choo, SP; Chow, PK; Gandhi, M; Goh, AS; Han, HS; Khin, MW; Lai, HK; Lim, TG; Lo, RH; Poon, DY; Singh, H; Soo, KC; Tan, SB; Tay, KH | 1 |
| Cai, G; Chen, H; Han, G; Liu, L; Qi, X; Wang, M; Zhao, Y | 1 |
| Haybaeck, J; Petru, E; Smolle, E; Taucher, V | 1 |
| Rexer, H | 2 |
| Bassett, RL; Busaidy, NL; Cabanillas, ME; Dadu, R; Habra, MA; Hu, MI; Jimenez, C; Sherman, SI; Waguespack, SG; Ying, AK | 1 |
| Beveridge, RD; Campos, GB; Daroqui, JC; Esparcia, MF; Estellés, DL; Huerta, ÁS; Imedio, ER; Ortiz, AG; Salcedo, JM; Urtasun, JA | 1 |
| Adachi, T; Akutsu, N; Hamamoto, Y; Hirayama, D; Igarashi, M; Kaneto, H; Motoya, M; Sasaki, S; Shinomura, Y; Shitani, M; Takagi, H; Wakasugi, H; Yamamoto, H; Yawata, A; Yonezawa, K | 1 |
| Miyahara, K; Nouso, K; Yamamoto, K | 1 |
| Fu, SR; He, X; Hu, BS; Huang, JW; Li, JP; Li, Y; Lu, LG; Zhan, MX; Zhang, YQ | 1 |
| Beeram, M; Benjamin, D; Ketchum, N; Mahalingam, D; Malik, L; Michalek, J; Mita, A; Rodon, J; Sankhala, K; Sarantopoulos, J; Tolcher, A; Wright, J | 1 |
| Llovet, JM | 1 |
| Bie, P; Chen, X; Hu, P; Zhang, L | 1 |
| Blacher, S; Calligaris, D; Cimino, J; De Pauw, E; De Tullio, P; Debois, D; Mari, B; Mazzucchelli, G; Noel, A; Paye, A; Primac, I; Sounni, NE; Truong, A | 1 |
| Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ | 1 |
| Anak, O; Assenat, E; Blanc, JF; Cattan, S; Chen, CL; Chen, LT; Daniele, B; Dorval, E; Furuse, J; Jappe, A; Kang, YK; Kudo, M; Lim, HY; Peck-Radosavljevic, M; Perraud, K; Poon, RT; Santoro, A; Sellami, DB; Vogel, A; Zhu, AX | 1 |
| Bai, M; Han, GH; Yang, M; Yuan, JQ | 1 |
| Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O; Yoshikawa, M | 1 |
| Koyanagi, T; Masumoto, A; Morita, Y; Motomura, K; Senju, T; Suzuki, H; Tajiri, H; Yada, M | 1 |
| Choi, GH; Han, S; Kang, YK; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH | 1 |
| Buonomano, P; Camera, L; Circelli, L; Colao, A; Del Prete, M; Di Somma, C; Faggiano, A; Marciello, F; Marotta, V; Modica, R; Ramundo, V; Rubino, M; Sciammarella, C | 1 |
| Bolondi, L; Boni, C; Bruzzi, P; Cammà, C; Colombo, M; Craxi, A; Danesi, R; Daniele, B; Di Costanzo, GG; Fagiuoli, S; Santoro, A; Spandonaro, F; Trevisani, F | 1 |
| Kudo, M; Shimada, M; Tanaka, K | 1 |
| Dai, C; Jia, C; Peng, S; Xu, F; Xu, Y; Zhao, Y | 1 |
| Abdel-Rehim, M; Castéra, L; Chatellier, G; Lebtahi, R; Ronot, M; Sibert, A; Vilgrain, V | 1 |
| Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ | 1 |
| Aglietta, M; Asaftei, SD; Bertulli, R; Biagini, R; Capozzi, F; Casali, PG; D'Ambrosio, L; Fagioli, F; Ferraresi, V; Ferrari, S; Gambarotti, M; Grignani, G; Marchesi, E; Palmerini, E; Picci, P; Pignochino, Y; Sangiolo, D; Tamburini, A | 1 |
| Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC | 1 |
| Boige, V; Ducreux, M; Ferté, C; Hollebecque, A; Malka, D | 1 |
| Andrade, R; Arenas, J; Bustamante, J; Castells, L; Díaz, R; Espinosa, MD; Fernández-Castroagudín, J; Gómez, M; Gonzálvez, ML; Granizo, IM; Hernandez-Guerra, M; Polo, BA; Rendón, P; Sala, M; Salgado, M; Serrano, T; Turnes, J; Vergara, M; Viudez, A | 1 |
| Choi, HJ; Han, J; Han, KH; Kim, GM; Lim, S | 1 |
| Chen, CY; Chen, SC; Feng, CW; Feng, YM; Lee, MY; Lu, CL | 1 |
| Araki, H; Gotoh, M; Hattori, R; Kimura, T; Sassa, N; Tanaka, K; Tsuzuki, T; Yamada, S; Yoshino, Y | 1 |
| Chen, C; Cheng, Z; Cong, WM; Ding, J; Feng, GS; Han, T; Li, HY; Liu, N; Shen, WF; Sun, HL; Sun, W; Wang, HY; Wang, RY; Wang, X; Wen, W; Wu, MC; Xiang, DM | 1 |
| Du, Z; He, X; Li, Q; Tang, R; Wen, F; Yang, Y; Zhang, J; Zhang, P; Zhou, J | 1 |
| Petrou, P | 1 |
| Fujie, S; Fukubayashi, K; Izumi, K; Kawasaki, T; Kikuchi, K; Naoe, H; Sasaki, Y; Setoyama, H; Tanaka, M; Tateyama, M; Watanabe, T; Yoshimaru, Y | 1 |
| Chang, E; Foerster, S; Gondek, L; Huso, DL; Levis, M; Li, L; Lim, Y; Ma, H; Marchionni, L; Matsui, W; McGovern, K; Merchant, AA; Peacock, CD; Small, D; Smith, BD; Wang, Q; Watkins, DN | 1 |
| Fan, W; Fu, S; Huang, J; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y; Zhu, K | 1 |
| Aedo, V; Cristina, V; Faivre, S; Raymond, E | 1 |
| Bu, W; Chen, H; Cong, N; Li, J; Shi, C; Song, J; Wang, L | 1 |
| Bruix, J; Di Donato, R; Gazzola, A; Reig, M | 1 |
| Hashimoto, Y; Iizuka, J; Kennoki, T; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K | 1 |
| Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P | 1 |
| Bao, WD; Chen, TW; Cheng, SQ; Deng, YZ; Feng, YY; Guan, DX; Koeffler, HP; Li, JJ; Long, LY; Qiu, L; Shi, J; Xie, D; Zhang, EB; Zhang, XL; Zhang, Y; Zhao, JS | 1 |
| Chen, Y; Chern, GG; Chiang, T; Gao, DY; Lin, TT; Liu, CH; Liu, JY | 1 |
| Abastado, JP; Chew, V; Ho, V; Kaldis, P; Lee, J; Lim, TS; Steinberg, J; Szmyd, R; Tham, M; Yaligar, J | 1 |
| Djokovic, D; Duarte, A; Gigante, J; Harris, AL; Pinho, M; Trindade, A | 1 |
| Berre, MA; Bolondi, L; Bruix, J; Cai, J; Chau, GY; Han, KH; Kudo, M; Lee, HC; Lee, KS; Llovet, JM; Makuuchi, M; Mazzaferro, V; Meinhardt, G; Poon, RT; Roayaie, S; Song, T; Souza, F; Tak, WY; Takayama, T; Yang, J | 1 |
| Devapatla, B; Sharma, A; Woo, S | 1 |
| Kanda, M; Kodera, Y; Sugimoto, H | 1 |
| Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O | 2 |
| Cao, G; Li, J; Li, X; Qin, C | 1 |
| Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Brandts, CH; Burchert, A; Dürk, H; Ehninger, G; Einsele, H; Frickhofen, N; Geer, T; Giagounidis, A; Görner, M; Hänel, M; Hase, J; Heits, F; Herbst, R; Hüttmann, A; Illmer, T; Junghanß, C; Kaiser, U; Kiani, A; Klut, IM; Krämer, A; Kramer, M; Krause, SW; Krug, U; Kullmer, J; Kunzmann, V; Link, H; Mackensen, A; Müller-Tidow, C; Neubauer, A; Noppeney, R; Parmentier, S; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Serve, H; Thiede, C; von Bonin, M | 1 |
| Grünwald, V; Ivanyi, P | 1 |
| Chen, P; Li, P; Lu, J; Lu, X; Wang, F; Wang, J; Wang, Q; Wang, Y; Wang, Z; Wu, G; Yuan, J; Zhang, L; Zheng, Y | 1 |
| Alsinet, C; Cabellos, L; Cornella, H; Desbois-Mouthon, C; Domingo-Domenech, J; Hoshida, Y; Llovet, JM; Lozano, JJ; Martinez-Quetglas, I; Moeini, A; Peix, J; Sia, D; Solé, M; Torrecilla, S; Tovar, V; Vidal, S; Villanueva, A | 1 |
| Ahn, H; Ahn, JH; Hong, B; Hong, JH; Jeong, IG; Koo, DH; Lee, DH; Lee, JL; Park, I; Song, C; You, D | 1 |
| de Castro, G; de Castroneves, LA; de Freitas, RM; Fukushima, JT; Hoff, AO; Hoff, PM; Jorge, AA; Kulcsar, MA; Lima, JV; Negrão, MV; Papadia, C; Simão, EF; Tavares, MR | 1 |
| Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A | 1 |
| Bhoori, S; Bongini, M; Facciorusso, A; Flores, M; Gasbarrini, A; Germini, A; Mazzaferro, V; Ponziani, FR; Sposito, C | 1 |
| Bronowicki, JP; Chen, XP; Dagher, L; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK | 1 |
| Mikagi, K; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y | 1 |
| Moriyasu, F; Saito, K; Shirota, N; Sugimoto, K; Takara, K; Tokuuye, K | 1 |
| Cho, BC; Choi, JH; Choi, JR; Heo, DS; Jung, M; Kang, SY; Kim, DW; Kim, HT; Kim, JH; Kim, SW; Lee, DH; Lim, SM; Shim, HS | 1 |
| Cao, Y; Chen, EB; Dai, Z; Fan, J; Hu, ZQ; Huang, XW; Wang, Z; Zhou, J; Zhou, SL; Zhou, ZJ | 1 |
| Furuse, J; Ikeda, K; Inuyama, L; Ito, Y; Kaneko, S; Matsuzaki, Y; Minami, H; Okayama, Y; Okita, K; Sunaya, T | 1 |
| Cai, X; Chang, C; Jin, RA; Li, G; Lin, H; Ma, WL; Shi, L; Sun, Y; Xu, J; Yeh, S | 1 |
| Bai, W; Duran, R; Fan, D; Gu, S; Guan, S; Guo, W; Han, G; Li, H; Liu, J; Lv, W; Ma, Y; Mu, W; Qin, X; Ren, W; Sahu, S; Wang, W; Wang, Y; Yin, Z; Zhang, Z; Zhao, Y | 1 |
| Bucci, L; Camelli, V; Garuti, F; Spinardi, L; Trevisani, F | 1 |
| Cai, XB; Hou, Y; Li, J; Liu, B | 1 |
| Fu, P; Li, Q; Wen, F; Wheeler, J; Yang, Y; Zhang, P | 1 |
| Keck, B; Lieb, V; Lüdecke, G; Sikic, D | 1 |
| Chen, Y; Ding, J; Fang, T; Guo, LN; Li, T; Liang, D; Lv, GS; Lv, HW; Tan, YX; Tang, L; Tang, SH; Wang, CZ; Wang, HY; Wu, FQ; Yang, W; Yu, LX | 1 |
| Chan, AL; Leung, HW; Liu, CF | 1 |
| Lv, L; Mei, ZC; Zeng, J | 1 |
| De Velasco, MA; Haji, S; Iida, H; Ishizaki, M; Kaibori, M; Kanazawa, A; Kitade, H; Kubo, S; Kwon, AH; Matsui, K; Matsushima, H; Nagano, H; Nishio, K; Sakai, K; Takeda, Y; Takemura, S; Tsukamoto, T; Wada, H | 1 |
| Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Noda, Y; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tanaka, M; Torimura, T | 1 |
| Chiba, T; Inoue, M; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Wakamatsu, T; Yokosuka, O | 1 |
| Brizzi, MP; Di Maio, M; Pignataro, D; Scagliotti, GV; Tampellini, M | 1 |
| Bruix, J; Reig, M; Ribeiro de Souza, A | 1 |
| Brower, V | 1 |
| Al-Khadimi, G; Allen, N; Chowdhury, R; Heaton, N; Korantzis, I; O'Grady, J; Papadatos-Pastos, D; Ross, PJ; Sarker, D; Suddle, A; Thillai, K; Ziogas, DC | 1 |
| Cai, Z; Han, Y; Liu, N; Liu, P; Shen, P; Wang, C | 1 |
| Bouattour, M; de Gramont, A; Faivre, S; Soubrane, O | 1 |
| Chen, S; Fu, S; Li, Y; Liang, C; Liu, Z; Lu, L; Zhu, Y | 1 |
| Forgez, P; Galmiche, A; Liu, J; Paradis, V; Segal-Bendirdjian, E; Stadler, N; Wendum, D; Wu, Z | 1 |
| Campitiello, M; Eid, N; Hennequin, L; Longo, R; Plastino, F; Quétin, P; Wendel, C | 1 |
| Bergadà, L; Boyd, J; Chen, BJ; Dolcet, X; Encinas, M; Eritja, N; Gatius, S; Llobet-Navàs, D; Martí, MD; Matias-Guiu, X; Ponce, J; Reventós, J; Ribera, J; Rodríguez-Barrueco, R; Santacana, M; Vidal, A; Villanueva, A; Yeramian, A | 1 |
| Arizumi, T; Bettinger, D; Burlone, ME; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sharma, R; Thimme, R; Ward, C; Yen, C | 1 |
| Akahori, T; Hokuto, D; Kanehiro, H; Kawaguchi, C; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiwada, S; Nomi, T; Obara, S; Sho, M; Yamada, T; Yamato, I; Yasuda, S; Yoshikawa, T | 1 |
| Dutta, R; Mahato, RI | 1 |
| Aikata, H; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, F; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kobayashi, T; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Teraoka, Y; Tsuge, M | 1 |
| Cheong, JY; Cho, HJ; Cho, SW; Hwang, JC; Kang, DR; Kim, B; Kim, JK; Kim, SS; Lee, JH; Lee, KJ; Lee, KM; Lim, SG; Nam, JS; Oh, MJ; Shin, SJ; Yang, MJ; Yoo, BM | 1 |
| Heinemann, V; Stemmler, HJ | 1 |
| Becker, M; Börgermann, C; Rose, A; Rübben, H; Vom Dorp, F | 1 |
| Kuczyk, MA; Merseburger, AS | 1 |
| Blanc, JF; Bolondi, L; Borbath, I; Bruix, J; de Oliveira, AC; Forner, A; Galle, PR; Gane, E; Giannaris, T; Greten, TF; Häussinger, D; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Porta, C; Raoul, JL; Ricci, S; Santoro, A; Schwartz, M; Seitz, JF; Shan, M; Voliotis, D; Zeuzem, S | 1 |
| Haseke, N; Karl, A; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K | 1 |
| Choi, JI; Kim, CM; Park, BJ; Park, JW; Shim, JH | 1 |
| Busch, AE; Dony, E; Ellinghaus, P; Ghofrani, HA; Grimminger, F; Klein, M; Milting, H; Nikolova, S; Pullamsetti, SS; Riedl, B; Savai, R; Schäfer, S; Schermuly, RT; Weissmann, N | 1 |
| Copur, MS | 1 |
| Chow, PK; Chung, A; Huynh, H; Lam, IW; Lee, JW; Lew, GB; Ngo, VC; Ong, HS; Soo, KC | 1 |
| Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K | 1 |
| Aburatani, H; Hirakawa, K; Iwata, C; Johansson, E; Kano, MR; Kiyono, K; Komuro, A; Matsumoto, Y; Miyazono, K; Miyoshi, H; Morishita, Y; Shirai, YT; Suzuki, HI; Watanabe, A; Yashiro, M | 1 |
| Jonkers, IJAM; van Buren, M | 1 |
| Rimassa, L; Santoro, A | 1 |
| Mendizabal, M; Reddy, KR | 1 |
| Kuszatal, E; Langiewicz, P; Nurzyński, P; Oborska, S; Obrocka, B; Szczylik, C; Waśko-Grabowska, A; Zołnierek, J | 1 |
| Aziz, SA; Camp, RL; Conrad, PJ; Jilaveanu, LB; Kluger, HM; Rimm, DL; Schmitz, JC; Sznol, M; Zito, CR | 1 |
| Carbonell, CE; Coleman, TA; Davis, CH; Davis, WB; La Vine, DB | 1 |
| Bolondi, L; Greten, TF; Lammer, J; Peck-Radosavljevic, M; Rosmorduc, O; Sangro, B; Santoro, A | 1 |
| Lieber, ML; Shah, SN; Smith, AD | 1 |
| Addeo, R; Bianco, M; Capasso, E; Caraglia, M; Cennamo, G; D'Agostino, A; Faiola, V; Febbraro, A; Guarrasi, R; Maiorino, L; Mamone, R; Montella, L; Montesarchio, V; Palmieri, G; Piai, G; Pisano, A; Prete, SD; Sabia, A; Savastano, C; Tarantino, L; Vincenzi, B | 1 |
| Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B | 1 |
| Gschwend, JE | 1 |
| Bali, MA; Devière, J; Maréchal, R; Van Laethem, JL; Verset, G | 1 |
| Bronstein, Y; Busaidy, NL; Cabanillas, ME; Feng, L; Hernandez, M; Lopez, A; Sherman, SI; Waguespack, SG; Williams, MD | 1 |
| Balsom, SM; Bekaii-Saab, TS; Bloomston, M; Li, X; Patel, T; Rose, J; Trolli, E | 1 |
| Albers, P; Bergmann, L; Gschwend, J; Jäger, E; Keilholz, U; Miller, K | 1 |
| Lieber, ML; Remer, EM; Rini, BI; Shah, SN; Smith, AD | 1 |
| Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH | 1 |
| Lee, YC; Park, YH; Roh, SY | 1 |
| Bayliss, S; Connock, M; Greenheld, W; Moore, D; Round, J; Tubeuf, S | 1 |
| Billemont, B; Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Massault, PP; Mir, O; Ropert, S; Vignaux, O | 1 |
| Fukasawa, S; Ichikawa, T; Imamura, Y; Komaru, A; Maruoka, M; Naya, Y; Nihei, N; Sazuka, T; Suyama, T; Ueda, T | 1 |
| Bukowski, RM; Escudier, B; Lathia, C; Peña, C; Shan, M | 1 |
| Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F | 1 |
| Chan, P; Pang, R; Poon, RT; Yau, T | 1 |
| Tomita, Y | 1 |
| Rowe, IA | 1 |
| Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC | 1 |
| Banerji, U; Berns, B; de Boer, C; Edmonds, K; Ferguson, TR; Gore, ME; James, MG; Larkin, JM; Pickering, LM; Thomas, K | 1 |
| Düber, C; Galle, PR; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA | 1 |
| Abou-Alfa, GK; Capanu, M; Davidenko, I; Gansukh, B; Johnson, P; Knox, JJ; Lacava, J; Leung, T; Saltz, LB | 1 |
| Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH | 1 |
| Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xie, XY; Ye, SL; Zhang, BH; Zhang, L | 1 |
| Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R | 1 |
| Benedict, A; Charbonneau, C; Figlin, RA; Hariharan, S; Harmenberg, U; Négrier, S; Remák, E; Sandin, R; Sandström, P; Ullén, A | 1 |
| Andreadis, C; Bamias, A; Dimopoulos, M; Karadimou, A; Kontovinis, L; Laschos, K; Papazisis, K; Paraskevopoulos, P | 1 |
| Cabrera, R; Cao, M; Gabrilovich, D; Liu, C; Nelson, DR; Xu, Y; Youn, JI; Zhang, X | 1 |
| Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Gouya, H; Legmann, P; Mir, O; Pol, S; Ropert, S; Sogni, P; Vignaux, O | 1 |
| Lanzuela, M; Lao, J; Pazo Cid, RA | 1 |
| Choi, JI; Kim, MJ; Lee, JS; Park, JW | 1 |
| Akladios, CY; Aprahamian, M; Balboni, G; Bour, G; Marescaux, J; Mutter, D | 1 |
| Takami, HE | 1 |
| Behnsawy, HM; Fujisawa, M; Fukuhara, T; Inoue, TA; Kusuda, Y; Miyake, H | 1 |
| Blumenstengel, K; Grimm, MO; Groschek, M; Herrmann, E; Hutzschenreuter, U; Marschner, N; Ohlmann, CH; Overkamp, F; Pühse, G; Steiner, T | 1 |
| Dai, B; Shen, YJ; Shi, GH; Wang, CF; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
| Busch, J; Flörcken, A; Grünwald, V; Johannsen, M; Keilholz, U; Kempkensteffen, C; Miller, K; Weikert, S; Weinkauf, L; Westermann, J; Zimmermann, K | 1 |
| Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Varga, Z | 1 |
| Chen, M; Orsini, LS; Qiao, YL; Therneau, T | 1 |
| Abbadessa, G; Carrillo-Infante, C; Cucchi, E; Pressiani, T; Rimassa, L; Santoro, A | 1 |
| Betlloch, I; Cuesta, L; Latorre, N; Monteagudo, A; Toledo, F | 1 |
| Chida, N; Furuse, J; Hayashi, N; Hori, T; Imanaka, K; Kaneko, S; Kudo, M; Kumada, H; Matsui, O; Meinhardt, G; Nakachi, K; Ohya, T; Okita, K; Okusaka, T; Suh, DJ; Tak, WY; Takayama, T; Tanaka, K; Tsubouchi, H; Wada, M; Yamaguchi, I; Yoon, JH | 1 |
| Ahn, HK; Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, SH; Park, YS; Sun, JM | 1 |
| Bergmann, L; Gschwend, J; Keilholz, U; Miller, K | 1 |
| Al-Osaimi, AM; Argo, CK; Caldwell, SH; Northup, PG; Schmitt, TM; Shah, NL; Truesdale, AE | 1 |
| Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Sakurai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N | 1 |
| Crespo, O; Daneman, R; Ho, PP; Kang, SC; Lindstrom, TM; Robinson, WH; Sobel, RA; Steinman, L | 1 |
| Cabibbo, G; Cammà, C; Colombo, M; Grieco, A; Iavarone, M; Piscaglia, F; Villa, E; Zavaglia, C | 1 |
| Bustamante, J; Castroagudin, JF; Garralda, E; Gomez-Martin, C; Herrero, I; Matilla, A; Salcedo, M; Sangro, B; Testillano, M | 1 |
| Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X | 1 |
| Galle, PR; Gamstätter, T; Niederle, IM; Schadmand-Fischer, S; Schuchmann, M; Spies, PR; Weinmann, A; Wörns, MA | 1 |
| Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dumas, G; Goldwasser, F; Mir, O; Rodrigues, MJ; Ropert, S; Rousseau, B | 1 |
| Asahina, Y; Hoshioka, T; Hosokawa, T; Itakura, J; Izumi, N; Kato, T; Kurosaki, M; Kuzuya, T; Nakanishi, H; Suzuki, Y; Takahashi, Y; Tamaki, S; Tanaka, K; Tsuchiya, K; Ueda, K; Yasui, Y | 1 |
| Allavena, P; Mantovani, A | 1 |
| Awada, A; Bartholomeus, S; Brendel, E; Christensen, O; de Valeriola, D; Delaunoit, T; Gil, T; Hendlisz, A; Lathia, CD; Lebrun, F; Piccart-Gebhart, M; Radtke, M | 1 |
| Chang, C; Hsu, CL; Huang, CK; Hung, YC; Jeng, LB; Lin, TY; Ma, WL; Wu, MH; Yeh, CC; Yeh, S | 1 |
| Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L | 1 |
| Bruix, J; Forner, A; Llovet, JM | 1 |
| Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS | 1 |
| Graziadei, I; Grünberger, B; Hucke, F; Kölblinger, C; Königsberg, R; Maieron, A; Müller, C; Peck-Radosavljevic, M; Pinter, M; Sieghart, W; Stauber, R; Vogel, W | 1 |
| Byrne, M; Estfan, B; Kim, R | 1 |
| Cho, M; Heo, J; Kang, DH; Kim, GH; Song, GA; Woo, HY; Yoon, KT | 1 |
| De Luca, M; Di Costanzo, GG; Iodice, L; Lampasi, F; Lanza, AG; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R | 1 |
| Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D | 1 |
| Abrahamova, J; Bortlicek, Z; Buchler, T; Melichar, B; Pavlik, T; Poprach, A; Vyzula, R | 1 |
| Altomare, E; Bargellini, I; Bartolozzi, C; Bertini, M; Bertoni, M; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Parisi, G; Romano, A; Sacco, R; Scaramuzzino, A; Tumino, E | 1 |
| Alberola, V; Bennouna, J; Biesma, B; Eisen, T; Gans, S; Gottfried, M; Heigener, D; Le Marie, E; Liao, M; Montegriffo, E; Ong, TJ; Paz-Ares, LG; Santoro, A; Strauss, UP; Sun, Y; Syrigos, K; Vansteenkiste, J; von Pawel, J; Zhang, L | 1 |
| Aikata, H; Chayama, K; Hiramatsu, A; Honda, Y; Kawaoka, T; Miyaki, D; Murakami, E; Naeshiro, N; Nagaoki, Y; Nakahara, T; Takahashi, S; Takaki, S; Tanaka, M; Waki, K | 1 |
| Addeo, R; Calvieri, A; Caraglia, M; Del Prete, S; Montella, L; Picardi, A; Santini, D; Silletta, M; Tonini, G; Vespasiani, U; Vincenzi, B | 1 |
| Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J | 1 |
| Bertossi, M; De Sanctis, R; De Vincenzo, F; Di Tommaso, L; Fattuzzo, G; Giordano, L; Lorenzi, E; Mancini, L; Masci, G; Perrino, M; Rimassa, L; Roncalli, MG; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA; Zuradelli, M | 1 |
| Aino, H; Fukuizumi, K; Iwamoto, H; Kajiwara, M; Koga, H; Kurogi, J; Kuromatsu, R; Matsugaki, S; Matsukuma, N; Nagamatsu, H; Nakano, M; Niizeki, T; Ono, N; Sakai, T; Sakata, K; Sata, M; Satani, M; Sumie, S; Tajiri, N; Takata, A; Tanaka, M; Torimura, T; Yamada, S; Yano, Y | 1 |
| Kikuchi, Y; Kudo, T; Maruyama, K; Shiozawa, K; Sumino, Y; Watanabe, M | 1 |
| Huang, GL; Liu, GJ; Lü, MD; Wang, W; Xie, XH; Xie, XY; Xu, M; Xu, ZF; Zheng, SG; Zheng, YL | 1 |
| Bearz, A; Berretta, M; Cacopardo, B; Dal Maso, L; De Re, V; Di Benedetto, F; Facchini, G; Fiorica, F; Garlassi, E; Lleshi, A; Nasti, G; Spina, M; Tirelli, U | 1 |
| Cappelleri, JC; Chen, C; Foley, G; Healey, PJ; Kroes, M; Larkin, J; Mitchell, S; Paine, A; Tumur, I | 1 |
| Brandt, R; Dredge, K; Hammond, E | 1 |
| Bai, W; Fan, DM; Han, GH; He, CY; Li, RJ; Qi, XS; Wang, YJ; Wu, KC; Xia, JL; Yin, ZX; Zhao, Y | 1 |
| Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X | 1 |
| Bartsch, DK; Buchholz, M; Fendrich, V; Holler, JP; Maschuw, K; Rehm, J; Slater, EP; Waldmann, J | 1 |
| Andrés, R; Arranz, JA; Cruz, J; del Muro, XG; Domenech, M; Gallardo, E; Maroto, JP; Meana, JA; Mellado, B; Perez-Gracia, JL | 1 |
| Hidaka, H; Koizumi, W; Kokubu, S; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M | 1 |
| Chien, DS; Wilhelm, S | 1 |
| Clark, JW; Eder, JP; Lathia, C; Lenz, HJ; Ryan, D | 1 |
| Escudier, B; Gore, ME | 1 |
| Bukowski, RM | 1 |
| Chami, L; Escudier, B; Lamuraglia, M; Lassau, N; Leclère, J; Roche, A; Schwartz, B | 1 |
| Figg, WD; Jain, L; Venitz, J | 1 |
| Stadler, W | 1 |
| Blanke, C | 1 |
| Bukowski, RM; Chevreau, C; Demkow, T; Desai, AA; Eisen, T; Escudier, B; Freeman, S; Gore, M; Hutson, TE; Negrier, S; Oudard, S; Rolland, F; Schwartz, B; Shan, M; Siebels, M; Simantov, R; Solska, E; Stadler, WM; Szczylik, C | 1 |
| Flaherty, KT | 1 |
| Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P | 1 |
| Agulnik, M; Cheiken, R; Chen, EX; Chin, SF; Elser, C; Elting, J; Francis, P; McNabola, A; Petrenciuc, O; Pond, GR; Siu, LL; Wilkie, D; Winquist, E | 1 |
| Chi, KN; Czaykowski, P; Ellard, SL; Gauthier, I; Hansen, C; Hotte, SJ; Moore, M; Ruether, JD; Schell, AJ; Seymour, L; Taylor, S; Walsh, W | 1 |
| Chu, D; Fillos, T; Lacouture, ME; Wu, S | 1 |
| Flaherty, KT; Gallagher, ML; Heitjan, DF; O'Dwyer, PJ; Rosen, MA; Schnall, MD; Schwartz, B | 1 |
| Bui, B; Italiano, A | 1 |
| Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E | 1 |
50 review(s) available for sorafenib and Disease Exacerbation
| Article | Year |
|---|---|
Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Liver Neoplasms; Neoplasm Staging; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Therapies, Investigational | 2020 |
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Humans; Iodine Radioisotopes; Meta-Analysis as Topic; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2019 |
Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Aspirin; Biological Products; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Enzyme Activators; Female; Humans; Metformin; Phosphorylation; Signal Transduction; Sorafenib; Treatment Outcome | 2020 |
New insights on sorafenib resistance in liver cancer with correlation of individualized therapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Drug Resistance, Neoplasm; Humans; Liver; Liver Neoplasms; Metabolic Clearance Rate; Neoplasm Staging; Patient Selection; Precision Medicine; Prognosis; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome; Tumor Microenvironment | 2020 |
Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Sorafenib; Survival Analysis; Treatment Outcome | 2022 |
Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Methylation; Methyltransferases; Molecular Targeted Therapy; Neoplasm Invasiveness; Nuclear Proteins; RNA, Long Noncoding; Sorafenib; Up-Regulation | 2021 |
Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Hand-Foot Syndrome; Humans; Liver Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Risk Factors; Sorafenib; Treatment Outcome | 2018 |
Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
Topics: Adult; Antineoplastic Agents; Disease Progression; Female; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed | 2017 |
Regorafenib: A Review in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Drug Approval; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2018 |
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors | 2018 |
Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Sorafenib; Treatment Outcome | 2018 |
Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Protein Kinase Inhibitors; Retrospective Studies; Severity of Illness Index; Sorafenib | 2018 |
Supplementary Sorafenib Therapies for Hepatocellular Carcinoma-A Systematic Review and Meta-Analysis: Supplementary Sorafenib for Liver Cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Anilides; Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Models, Animal; Molecular Targeted Therapy; Pharmacokinetics; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; Treatment Outcome | 2019 |
Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Humans; Hypertension; Hypokinesia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Skin Diseases; Sorafenib; Survival | 2013 |
Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Fatal Outcome; Humans; Immunohistochemistry; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Rare Diseases; Risk Assessment; Sorafenib; Tomography, X-Ray Computed | 2013 |
Sorafenib in metastatic thyroid cancer: a systematic review.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms | 2014 |
Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors | 2014 |
Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; Disease Progression; Epithelial-Mesenchymal Transition; Female; Histone Deacetylase Inhibitors; Humans; Molecular Targeted Therapy; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Signal Transduction; Sorafenib; Transforming Growth Factor beta1; Treatment Outcome | 2014 |
Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Hepatic Artery; Humans; Liver Neoplasms; Medical Oncology; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Amplification; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Macrophages; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
Topics: Aged; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors | 2014 |
Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Publication Bias; Sorafenib; Treatment Outcome | 2014 |
Refining sorafenib therapy: lessons from clinical practice.
Topics: Age Factors; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retreatment; Sorafenib; Treatment Outcome | 2015 |
An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Patient Safety; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2014 |
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Drugs, Investigational; Humans; Liver Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Failure | 2015 |
[Advanced hepatocellular carcinoma: importance of clinical trials].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib | 2015 |
Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Interleukin-6; Liver Neoplasms; Membrane Glycoproteins; Microtubule-Associated Proteins; Neoplasm Recurrence, Local; Niacinamide; Nuclear Proteins; Oncogenes; Phenylurea Compounds; Prognosis; Receptors, Immunologic; Sirtuin 1; Sorafenib; Trans-Activators; Transcription Factors; Treatment Outcome; Triggering Receptor Expressed on Myeloid Cells-1 | 2015 |
Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Observational Studies as Topic; Phenylurea Compounds; Polymorphism, Genetic; Prognosis; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2015 |
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2015 |
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2016 |
Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Design; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Selection; Phenylurea Compounds; Randomized Controlled Trials as Topic; Research Design; Sorafenib | 2016 |
Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2016 |
Recent advances in hepatocellular carcinoma therapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease Progression; Drug Delivery Systems; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2017 |
[Oncology 2008].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Combined Modality Therapy; Disease Progression; Epothilones; Humans; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2008 |
[Value of targeted therapies for renal cell cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2008 |
Current management of hepatocellular carcinoma.
Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease Progression; Hepatectomy; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Liver Transplantation; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Drugs, Investigational; Everolimus; Evidence-Based Medicine; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2010 |
Sorafenib for the treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Humans; Liver Neoplasms; Models, Economic; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib; Survival Analysis; Treatment Outcome; United Kingdom | 2010 |
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
Topics: Anilides; Benzenesulfonates; Disease Progression; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2011 |
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Chemotaxis; Clodronic Acid; Cytokines; Dioxoles; Disease Progression; Humans; Immunity, Innate; Inflammation; Liposomes; Macrophages; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Tetrahydroisoquinolines; Trabectedin; Tumor Escape; Tumor Microenvironment | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Ultrasonography | 2012 |
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
BAY 43-9006: preclinical data.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Disease Progression; Humans; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2002 |
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Drug Delivery Systems; Endpoint Determination; Floxuridine; Fluorouracil; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk; Sorafenib; Survival Analysis; Treatment Outcome | 2006 |
Sorafenib in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Humans; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Research Design; Sorafenib; Time Factors | 2007 |
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Eruptions; Foot; Hand; Humans; Incidence; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk Assessment; Risk Factors; Skin; Skin Diseases; Sorafenib | 2008 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
74 trial(s) available for sorafenib and Disease Exacerbation
| Article | Year |
|---|---|
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease Progression; Humans; Sorafenib; Stomach Neoplasms; Treatment Outcome | 2023 |
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.
Topics: Bronchiolitis Obliterans Syndrome; Disease Progression; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Sorafenib | 2023 |
Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Exons; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Nucleophosmin; Remission Induction; Sorafenib; Transplantation, Homologous; Young Adult | 2020 |
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Sorafenib; Survival Rate | 2020 |
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Egypt; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Metformin; Middle Aged; Prognosis; Progression-Free Survival; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Sorafenib; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2021 |
Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Management; Disease Progression; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retreatment; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2020 |
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Sorafenib; Time Factors; Treatment Outcome | 2020 |
Efficacy of Ramucirumab
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Ramucirumab; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Europe; Female; Follow-Up Studies; Humans; Interleukin-6; Interleukin-8; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Sorafenib; Survival Analysis; Turkey; Young Adult | 2022 |
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Carcinoma, Hepatocellular; China; Disease Progression; Female; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Sorafenib; Time Factors; Young Adult | 2021 |
Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Outcome | 2017 |
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Response Evaluation Criteria in Solid Tumors; Safety; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class.
Topics: Aged; Asian People; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2018 |
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Europe; Female; Humans; Indoles; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Sorafenib; Treatment Outcome | 2018 |
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2018 |
Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2018 |
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Germany; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Sorafenib; Time Factors; Topoisomerase I Inhibitors; Topotecan | 2018 |
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Sorafenib; Survival Analysis; Urologic Neoplasms | 2018 |
Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Computer Simulation; Cost-Benefit Analysis; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Liver Neoplasms; Markov Chains; Middle Aged; Monte Carlo Method; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years; Sorafenib; Treatment Outcome | 2018 |
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer.
Topics: Cell Differentiation; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Male; Models, Biological; Neoplasm Staging; Progression-Free Survival; Sorafenib; Thyroid Neoplasms | 2019 |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Asia; B7-H1 Antigen; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Nivolumab; Sorafenib; Treatment Outcome; Young Adult | 2019 |
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Carcinoma, Hepatocellular; Case-Control Studies; Disease Progression; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Quinolines; Receptors, Transforming Growth Factor beta; Safety; Sorafenib; Transforming Growth Factor beta1; Treatment Outcome | 2019 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome | 2013 |
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Pharmacological; Cohort Studies; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Genital Neoplasms, Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Predictive Value of Tests; Proto-Oncogene Proteins c-akt; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Everolimus; Feasibility Studies; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; France; Head and Neck Neoplasms; Hemangioendothelioma, Epithelioid; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rare Diseases; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid | 2013 |
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Survival Analysis; Temozolomide; Time Factors | 2013 |
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Time Factors; TOR Serine-Threonine Kinases; Treatment Failure; Young Adult | 2014 |
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Disease Progression; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Salivary Gland Neoplasms; Sorafenib | 2015 |
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib | 2014 |
Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Time Factors; Yttrium Radioisotopes | 2014 |
[First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of pat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Survival Rate; Young Adult | 2014 |
Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Safety; Sorafenib; Survival Rate | 2014 |
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Disease Progression; Drug Monitoring; Early Termination of Clinical Trials; Feasibility Studies; Female; Hand-Foot Syndrome; Humans; Hypertension; Kinetics; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Sorafenib; Vascular Endothelial Growth Factors | 2014 |
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Everolimus; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; Survival Analysis; Young Adult | 2014 |
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Protocols; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Embolization, Therapeutic; France; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Research Design; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult | 2015 |
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Intention to Treat Analysis; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Niacinamide; Osteosarcoma; Phenylurea Compounds; Sirolimus; Sorafenib; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2015 |
[Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Salvage Therapy; Severity of Illness Index; Sorafenib; Spain; Treatment Outcome | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Double-Blind Method; Europe; Female; Hepatectomy; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; New Zealand; Niacinamide; North America; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; South America; Time Factors; Treatment Outcome; Young Adult | 2015 |
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease Progression; Exanthema; Fatigue; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Serum Albumin; Serum Albumin, Human; Sorafenib; Treatment Outcome | 2015 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Recurrence; Risk Factors; Sorafenib; Time Factors; Transplantation, Homologous; Treatment Outcome | 2015 |
Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors | 2016 |
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Risk Factors; Sorafenib; Treatment Outcome | 2016 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Survival Analysis | 2008 |
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Octreotide; Phenylurea Compounds; Pyridines; Sorafenib; Survival; Treatment Outcome | 2010 |
A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Medical Oncology; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2010 |
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Topics: Aged; Antigens, Neoplasm; Benzenesulfonates; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins p21(ras); Pyridines; Sorafenib; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
Topics: Aminoimidazole Carboxamide; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease Progression; Female; Humans; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Infliximab; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2010 |
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Doxorubicin; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Survival Rate; Thrombocytopenia; Young Adult | 2010 |
Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; China; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2011 |
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Regional Blood Flow; Sorafenib; Survival Analysis | 2011 |
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Japan; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Republic of Korea; Sorafenib; Survival Analysis; Treatment Outcome | 2011 |
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Diarrhea; Disease Progression; Drug Therapy, Combination; Everolimus; Female; Humans; Immunosuppressive Agents; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Distribution; Treatment Outcome; Young Adult | 2011 |
[Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiang
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma, Renal Cell; Disease Progression; Female; Germany; Humans; Kidney Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor A | 2011 |
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cohort Studies; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Taxoids; Treatment Outcome | 2012 |
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Double-Blind Method; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib | 2012 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Topics: Aged; Alcoholism; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Hand-Foot Syndrome; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Severity of Illness Index; Sorafenib; Time Factors; Tumor Burden | 2012 |
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome | 2012 |
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib | 2013 |
Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Prospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2013 |
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution | 2013 |
Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Time Factors | 2005 |
Randomized discontinuation trial of sorafenib (BAY 43-9006).
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Double-Blind Method; Drug Administration Schedule; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Reproducibility of Results; Research Design; Sorafenib; Treatment Outcome | 2006 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2007 |
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Survival Rate | 2007 |
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzenesulfonates; Biomarkers, Tumor; Canada; Cell Proliferation; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2008 |
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pilot Projects; Proto-Oncogene Proteins c-raf; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Analysis | 2008 |
217 other study(ies) available for sorafenib and Disease Exacerbation
| Article | Year |
|---|---|
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Humans; MAP Kinase Kinase Kinase 1; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Xenograft Model Antitumor Assays | 2004 |
Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Phenylurea Compounds; Propensity Score; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Risk Factors; Salvage Therapy; Sorafenib; Survival Analysis; Taiwan | 2022 |
KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Disease Progression; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Acetyltransferases; Humans; Liver Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Transcription Factors | 2021 |
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Kidney Neoplasms; Nivolumab; Pyridines; Retrospective Studies; Sorafenib | 2022 |
Prospective Observational Study of Sorafenib in Hepatocellular Carcinoma Patients With Very High Risk of Recurrence After Surgery.
Topics: Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Prospective Studies; Sorafenib | 2022 |
Upregulation of lncRNA PTOV1-AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR-505.
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Neoplasm Proteins; RNA, Long Noncoding; Sorafenib; Up-Regulation | 2023 |
Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression.
Topics: Animals; Antineoplastic Agents; Carbazoles; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; High Mobility Group Proteins; Histone Chaperones; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Sorafenib; Transcription Factors; Transcriptional Elongation Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation.
Topics: Adult; Aged; Allografts; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Period; Retrospective Studies; Sorafenib; Survival Analysis; Time Factors; Time-to-Treatment; TOR Serine-Threonine Kinases; Treatment Outcome | 2020 |
Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Everolimus; Humans; Mice; Osteosarcoma; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis | 2019 |
Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma.
Topics: Base Sequence; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neovascularization, Pathologic; Prognosis; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2019 |
Presentation and Outcomes of Hepatocellular Carcinoma in the Arabian Peninsula: A Review of a Single Institution Experience in the Sorafenib Era.
Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Kuwait; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index; Sex Factors; Sorafenib; Treatment Outcome | 2021 |
The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Carcinoma, Hepatocellular; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Disease Progression; Drug Design; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Mutagenesis; Neoplasm Invasiveness; Neoplasm Transplantation; Rats; Rats, Sprague-Dawley; Sorafenib | 2020 |
Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Claudin-4; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Sorafenib; Transcriptional Activation; Transfection; Up-Regulation; Xenograft Model Antitumor Assays; Zinc Fingers | 2020 |
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Carcinoma, Hepatocellular; Comparative Effectiveness Research; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Outcome and Process Assessment, Health Care; Phenylurea Compounds; Progression-Free Survival; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2020 |
Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2020 |
Galectin-3 expression and secretion by tumor-associated macrophages in hypoxia promotes breast cancer progression.
Topics: Adenocarcinoma; Animals; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Clodronic Acid; Coculture Techniques; Disease Progression; Female; Galectin 3; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Lymphatic Metastasis; Macrophages; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pectins; Signal Transduction; Sorafenib | 2020 |
Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Ramucirumab; Retrospective Studies; Sorafenib; Survival Rate | 2020 |
Long non‑coding RNA PLK1S1 was associated with renal cell carcinoma progression by interacting with microRNA‑653 and altering C‑X‑C chemokine receptor 5 expression.
Topics: Adult; Aged; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Nephrectomy; Receptors, CXCR5; RNA, Long Noncoding; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Sarcopenia; Sorafenib | 2020 |
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness.
Topics: Acetylation; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Energy Metabolism; Gene Expression Profiling; Gene Silencing; Glycolysis; Hep G2 Cells; Histone Deacetylases; Histones; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Prognosis; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Signal Transduction; Sorafenib; Spheroids, Cellular; Tumor Stem Cell Assay | 2021 |
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Costs; Female; Humans; Liver Neoplasms; Male; Middle Aged; Mortality; Progression-Free Survival; Proportional Hazards Models; Quality-Adjusted Life Years; Sorafenib; Treatment Outcome | 2021 |
Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.
Topics: Animals; Apoptosis; Autophagy; bcl-2-Associated X Protein; Beclin-1; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Survival Rate; Xenograft Model Antitumor Assays | 2021 |
Targeted therapy in Xp11 translocation renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Crizotinib; Disease Progression; Everolimus; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Nivolumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib; Tomography, X-Ray Computed | 2021 |
CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Disease Progression; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; MicroRNAs; Promoter Regions, Genetic; RNA, Circular; Sorafenib | 2021 |
Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Female; Humans; Inflammation; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Progression-Free Survival; Pyridines; Retrospective Studies; Sorafenib | 2021 |
Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Failure; Treatment Outcome | 2017 |
Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Analysis; Taiwan; Time Factors; Treatment Outcome | 2018 |
Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dioxygenases; Disease Progression; Histone Demethylases; Histones; Humans; Ikaros Transcription Factor; Liver Neoplasms; Methylation; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Signal Transduction; Sorafenib; Transplantation, Heterologous | 2017 |
Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatic Artery; HMGB1 Protein; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Sorafenib; Survival Rate; Young Adult | 2018 |
Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib | 2017 |
Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Disease Progression; Enzyme Activation; Extracellular Matrix; Extracellular Signal-Regulated MAP Kinases; Humans; Hyperthermia, Induced; Liver Neoplasms, Experimental; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm, Residual; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vitamin K 1; Xenograft Model Antitumor Assays | 2017 |
Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Decision-Making; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Reproducibility of Results; Retreatment; Retrospective Studies; Risk Factors; Serum Albumin, Human; Sorafenib; Treatment Failure | 2018 |
Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Fluorescent Dyes; Fluorodeoxyglucose F18; Humans; Mice, Transgenic; Molecular Imaging; Neoplasm Transplantation; Niacinamide; Optical Imaging; Phenylurea Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Random Allocation; Receptors, Bombesin; Receptors, Transferrin; Sorafenib; Treatment Outcome; Tumor Burden | 2017 |
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Germany; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Sorafenib; Stem Cell Transplantation; Tandem Repeat Sequences; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Angiopoietin-2; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Liver Neoplasms; Mice; Neoplasm Staging; Neovascularization, Pathologic; Nuclear Proteins; Sorafenib; Transcription Factors | 2018 |
Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Decision-Making; Disease Progression; Disease-Free Survival; Egypt; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Young Adult | 2018 |
Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Treatment of advanced hepatocellular carcinoma: beyond sorafenib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Controlled Clinical Trials as Topic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis | 2018 |
Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Sorafenib; Survival Rate | 2018 |
Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2018 |
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Multivariate Analysis; Neutropenia; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Thrombocytopenia; Treatment Outcome | 2018 |
The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report.
Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Fatal Outcome; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2018 |
Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Population Groups; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2018 |
Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study.
Topics: Aged; Analysis of Variance; Carcinoma, Hepatocellular; Catheter Ablation; Clinical Decision-Making; Cohort Studies; Databases, Factual; Disease Progression; Disease-Free Survival; Female; Hepatectomy; Humans; Infusions, Intra-Arterial; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Reproducibility of Results; Retrospective Studies; Risk Assessment; Sorafenib; Statistics, Nonparametric; Survival Analysis | 2018 |
Sorafenib in patients with progressed and refractory bone tumors.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Disease Progression; Female; Follow-Up Studies; Humans; Male; Retrospective Studies; Sorafenib; Young Adult | 2018 |
Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen Type I; Disease Progression; Epithelial-Mesenchymal Transition; Extracellular Matrix; Humans; Hyperthermia, Induced; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Metastasis; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome; Tumor Burden; Young Adult | 2019 |
Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Egypt; Female; Health Expenditures; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Middle Aged; Models, Econometric; Palliative Care; Quality-Adjusted Life Years; Sorafenib | 2019 |
The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Pyridines; Sorafenib | 2018 |
Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cytokines; Disease Progression; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome | 2019 |
UBE2C functions as a potential oncogene by enhancing cell proliferation, migration, invasion, and drug resistance in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neoplasm Invasiveness; Sorafenib; Ubiquitin-Conjugating Enzymes | 2019 |
Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Organic Cation Transport Proteins; Sorafenib; Transcription Factors | 2019 |
Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma.
Topics: Adult; Angiography, Digital Subtraction; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2019 |
Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance.
Topics: Adult; Antineoplastic Agents; Apoptosis; Basic-Leucine Zipper Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Genes, jun; Humans; Immunoprecipitation; Leucine Zippers; Liver Neoplasms; Male; Prognosis; Sorafenib | 2019 |
Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Tumor Burden | 2020 |
Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Topics: Aged; Antigens, CD; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Disease Progression; Female; Hepatitis A Virus Cellular Receptor 2; Humans; Immunotherapy; Liver Neoplasms; Lymphocyte Activation Gene 3 Protein; Male; Neoplasm Staging; Predictive Value of Tests; Prognosis; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Sorafenib; Up-Regulation | 2019 |
Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Topics: Aged; Argentina; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Phenylurea Compounds; Prospective Studies; Quinolines; Retrospective Studies; Sorafenib; Treatment Outcome | 2019 |
Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Comorbidity; Disease Progression; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Quality of Life; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2013 |
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Kidney Neoplasms; Models, Statistical; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
Topics: Animals; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Humans; Mice; Mice, SCID; Models, Biological; Molecular Targeted Therapy; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Model-based drug development in oncology: what's next?
Topics: Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Kidney Neoplasms; Models, Statistical; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.
Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Radiography; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome | 2013 |
Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Endpoint Determination; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Ultrasonography | 2013 |
In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; British Columbia; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Insurance Coverage; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Signal Transduction; Sorafenib; Time Factors; Treatment Outcome | 2014 |
Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2013 |
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up.
Topics: Adult; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lung Neoplasms; Mediastinal Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2013 |
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cytokines; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2014 |
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2014 |
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2014 |
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Disease-Free Survival; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |
Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Analysis; Withholding Treatment | 2014 |
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeodomain Proteins; Humans; Indoles; Lipids; Metabolomics; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteomics; Pyrroles; RNA Interference; Sorafenib; Sunitinib; Transplantation, Heterologous | 2014 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis | 2015 |
Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Drug Resistance, Neoplasm; Female; Hepatic Artery; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden | 2014 |
Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sorafenib; Survival Rate | 2017 |
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.
Topics: Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Indoles; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Failure | 2015 |
Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Hepatectomy; Humans; Japan; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib; Survivors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B, Chronic; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Radiography; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; DNA, Viral; Drug Therapy, Combination; Female; Forecasting; Hepatitis B virus; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Survival Rate; Viral Load; Virus Activation | 2015 |
Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Cyproheptadine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |
Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Grading; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Sorafenib | 2015 |
PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 11; raf Kinases; Sorafenib | 2015 |
Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
Cost-effectiveness analysis of axitinib through a probabilistic decision model.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Sorafenib; Uncertainty | 2015 |
Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2015 |
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.
Topics: Animals; Cell Compartmentation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Leukemia, Myeloid, Acute; Mice; Mutant Proteins; Myeloproliferative Disorders; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Sorafenib; STAT5 Transcription Factor; Stem Cells; Veratrum Alkaloids; Zinc Finger Protein Gli2 | 2015 |
Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quality of Life; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Assessment; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Young Adult | 2014 |
Systemic Treatment: Expecting Further Success.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A | 2015 |
Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Renal Dialysis; Retrospective Studies; Risk Assessment; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
Topics: Adult; Animals; Apoptosis; Case-Control Studies; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endometriosis; Endometrium; Extracellular Signal-Regulated MAP Kinases; Female; Heterografts; Humans; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Stromal Cells; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Disease Progression; Epithelial Cell Adhesion Molecule; Humans; Liver Neoplasms; Mice; Neoplastic Stem Cells; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Sorafenib; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2015 |
Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Topics: Angiogenesis Inhibitors; Animals; Benzylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Disease Progression; Genetic Therapy; Heterocyclic Compounds; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Receptors, CXCR4; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2015 |
TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboxymethylcellulose Sodium; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Humans; Immune System; Immunosuppressive Agents; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Poly I-C; Polylysine; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Toll-Like Receptor 3 | 2015 |
Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Calcium-Binding Proteins; Disease Progression; Down-Regulation; Gene Deletion; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Neovascularization, Pathologic; Niacinamide; Papilloma; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; Receptors, Interleukin-8B; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; China; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2015 |
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Topics: Aged; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factors; Gene Expression; Gene Expression Profiling; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Receptor, Fibroblast Growth Factor, Type 1; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Somatomedins; Sorafenib; Spheroids, Cellular; Survival Rate; Xenograft Model Antitumor Assays | 2017 |
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Time Factors; Withholding Treatment | 2016 |
Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Time Factors; Treatment Outcome | 2016 |
Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Polyethylene Glycols; Protein Precursors; Prothrombin; Recombinant Proteins; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A | 2016 |
Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Sorafenib; Time Factors; Withholding Treatment; Young Adult | 2016 |
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Radiography; Sorafenib; Treatment Outcome | 2016 |
Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Algorithms; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; raf Kinases; Remission Induction; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2016 |
Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Macrophages; Mice; Neutrophil Infiltration; Neutrophils; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocytes, Regulatory | 2016 |
Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Child; Diarrhea; Disease Progression; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Hypertension; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Patient Acuity; Phenylurea Compounds; Product Surveillance, Postmarketing; Prospective Studies; Sex Factors; Sorafenib; Survival Rate; Withholding Treatment; Young Adult | 2016 |
Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cytotoxicity, Immunologic; Disease Models, Animal; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy, Adoptive; Interleukin-12 Subunit p35; Killer Cells, Natural; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Receptors, Androgen; Signal Transduction; Sorafenib; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2016 |
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease Progression; Fatal Outcome; Humans; Jaw; Liver Neoplasms; Male; Niacinamide; Osteonecrosis; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed | 2016 |
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Female; Hepatitis B; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Middle Aged; Models, Economic; Niacinamide; Phenylurea Compounds; Quality of Life; Quality-Adjusted Life Years; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2016 |
ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Receptors, Adrenergic, beta-2; Signal Transduction; Sorafenib | 2016 |
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Making; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Markov Chains; Monte Carlo Method; Niacinamide; Phenylurea Compounds; Probability; Quality-Adjusted Life Years; Radiosurgery; Randomized Controlled Trials as Topic; Sorafenib; Taiwan | 2016 |
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Case-Control Studies; Disease Progression; Female; Fibroblast Growth Factors; Gene Dosage; High-Throughput Nucleotide Sequencing; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Fibroblast Growth Factor; Remission Induction; Retrospective Studies; Sequence Analysis, DNA; Sorafenib; Treatment Outcome | 2016 |
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Substitution; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Retreatment; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2016 |
Sorafenib plus cisplatin for hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2016 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; London; Male; Middle Aged; Multivariate Analysis; Niacinamide; Odds Ratio; Patient Selection; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2017 |
Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Ginkgo biloba; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Plant Extracts; Prospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Young Adult | 2017 |
Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Neurotensin; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Transfection | 2017 |
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurosurgical Procedures; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Disease Progression; Endometrial Neoplasms; Endoplasmic Reticulum Stress; Enzyme Activation; Female; Humans; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Databases, Factual; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Prospective Studies; Sorafenib | 2017 |
[A Case of Advanced Hepatocellular Carcinoma, Its Disease Progression Could Be Controlled by Multimodal Treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Disease Progression; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Time-to-Treatment; Treatment Outcome | 2017 |
Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Cytokines; Disease Progression; Disease-Free Survival; Female; Hepatitis B; Humans; Interleukin-17; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Risk Factors; Sorafenib | 2017 |
[Targeted therapy for metastatic bladder cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Transitional Cell; Disease Progression; Drug Delivery Systems; Gefitinib; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Sorafenib; Survival Rate; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
[Systemic therapy of metastasizing renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2008 |
Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B; Hepatitis C; Humans; Korea; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2009 |
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Topics: Animals; Benzamides; Benzenesulfonates; Blood Pressure; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Heart; Heart Ventricles; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Pulmonary Artery; Pyridines; Pyrimidines; raf Kinases; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Ventricular Remodeling | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate | 2008 |
Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Body Weight; Disease Models, Animal; Disease Progression; Exons; Gastrointestinal Stromal Tumors; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2009 |
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunohistochemistry; Lentivirus Infections; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Signal Transduction; Smad2 Protein; Sorafenib; Stomach Neoplasms; Thrombospondin 1; Transforming Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2009 |
Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.
Topics: Angiogenesis Inhibitors; Antihypertensive Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Disease Progression; Glomerulonephritis, IGA; Humans; Hypertension; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Sorafenib; Transplantation, Homologous | 2009 |
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Humans; Liver Function Tests; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sorafenib; Survival Rate | 2009 |
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Disease Progression; Drug Delivery Systems; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Disease Progression; Female; Gene Silencing; Humans; Indoles; Male; Melanoma; Middle Aged; Nevus; Niacinamide; Phenols; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Sensitivity and Specificity; Skin Neoplasms; Sorafenib; Young Adult | 2009 |
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2010 |
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Sorafenib | 2010 |
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Topics: Adult; Aged; Analysis of Variance; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Eruptions; Exanthema; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis | 2010 |
Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
Topics: Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Carcinoma, Hepatocellular; Disease Progression; Fatal Outcome; Hemobilia; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stents | 2010 |
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Off-Label Use; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Drug Delivery Systems; Everolimus; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Eruptions; Female; Hematologic Diseases; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2010 |
Effect of sorafenib on experimental choroidal neovascularization in the rat.
Topics: Animals; Benzenesulfonates; Choroidal Neovascularization; Computer Systems; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; Fluorescein Angiography; Gene Expression; Intercellular Adhesion Molecule-1; Lasers; Male; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyridines; Radiation Injuries; Rats; Rats, Inbred BN; Sorafenib; Vascular Endothelial Growth Factor A | 2010 |
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Topics: Adult; Benzenesulfonates; Disease Progression; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease Progression; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2010 |
Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Drug Screening Assays, Antitumor; Endothelium, Vascular; Fluorescent Antibody Technique, Direct; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Pericytes; Phenylurea Compounds; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease Progression; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Retrospective Studies; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Failure; Treatment Outcome | 2010 |
[Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diarrhea; Disease Progression; Follow-Up Studies; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Survival Rate | 2010 |
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Markov Chains; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib; Sweden; United States | 2011 |
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors | 2012 |
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
Topics: Animals; Benzenesulfonates; Bone Marrow Cells; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Disease Progression; Immunity, Cellular; Liver Neoplasms; Mice; Mice, Inbred BALB C; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Spleen; T-Lymphocytes, Regulatory | 2011 |
Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Doxorubicin; Endpoint Determination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Reproducibility of Results; Sorafenib; Treatment Outcome | 2011 |
Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Republic of Korea; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2011 |
[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Deoxycytidine; Disease Models, Animal; Disease Progression; Doxorubicin; Drug Monitoring; Gemcitabine; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Rats; Rats, Inbred ACI; Sorafenib; Survival Analysis; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2011 |
Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2013 |
Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Blood Sedimentation; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Kinetics; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Sorafenib | 2011 |
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Data Collection; Disease Progression; Drug Delivery Systems; Everolimus; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; China; Disease Progression; Humans; Liver Neoplasms; Longitudinal Studies; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib | 2011 |
Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Severe sorafenib-induced hand-foot skin reaction.
Topics: Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Hepatocellular; Clobetasol; Disease Progression; Drug Eruptions; Fatal Outcome; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2012 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cooperative Behavior; Cytokines; Disease Progression; Everolimus; Evidence-Based Medicine; Humans; Indazoles; Indoles; Interdisciplinary Communication; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Care Team; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Sorafenib; Time Factors; Treatment Outcome; Waiting Lists | 2011 |
Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Pyridines; Radiography; Sorafenib; Survival Analysis | 2011 |
Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.
Topics: Animals; Anisoles; Astrocytes; Benzamides; Benzenesulfonates; Cell Differentiation; Cell Proliferation; Cells, Cultured; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Imatinib Mesylate; Macrophages; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Platelet-Derived Growth Factor; Sorafenib; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2011 |
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib; Survival Analysis | 2011 |
AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Humans; Image Processing, Computer-Assisted; Liver; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Neoplasm Invasiveness; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2011 |
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Pyridines; Sorafenib | 2011 |
Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.
Topics: Animals; Anoikis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Knockout; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Random Allocation; Receptors, Androgen; Sorafenib; Tumor Cells, Cultured | 2012 |
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Ultrasonography | 2012 |
Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; Contrast Media; Disease Progression; Doxorubicin; Ethiodized Oil; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Databases, Factual; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sorafenib; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2013 |
Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Failure; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Time Factors | 2012 |
Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Pyridines; Radiography; Sorafenib | 2012 |
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2012 |
Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Skin Diseases; Sorafenib; Treatment Outcome | 2012 |
Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Protein Precursors; Prothrombin; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2012 |
Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2012 |
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyridines; raf Kinases; Risk Factors; Safety; Sorafenib; Survival Rate | 2013 |
Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Disease Progression; Ferric Compounds; Humans; Iron; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Phenylurea Compounds; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2012 |
Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
Topics: Animals; Antineoplastic Agents; Catheter Ablation; Combined Modality Therapy; Disease Progression; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.
Topics: Adult; Aged; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Hepatocellular; Disease Progression; Female; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Glucuronidase; Human Umbilical Vein Endothelial Cells; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Saponins; Sorafenib | 2012 |
Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.
Topics: Adenoma, Islet Cell; Animals; Antigens, Polyomavirus Transforming; Apoptosis; Disease Progression; Female; Insulin; Islets of Langerhans; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinase Inhibitors; Rats; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden | 2012 |
Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Precursors; Prothrombin; Retrospective Studies; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Community Health Services; Cytokines; Disease Progression; Drug Delivery Systems; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Failure | 2006 |
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phospholipids; Pilot Projects; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Sulfur Hexafluoride; Survival Analysis; Treatment Outcome; Ultrasonography, Doppler | 2006 |
New therapeutic options for renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Current and future management of GIST.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed | 2007 |
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate | 2007 |